Hematological Drugs

Hematological APIs include anticoagulants, antiplatelet agents, hematopoietic stimulants, hemostatic agents, and anemia-correction compounds. They support treatments for thrombosis, bleeding disorders, anemia, leukemia adjunct therapy, and surgical risk control. These APIs require strict purity control due to their systemic effects and high clinical sensitivity.

Hemostatics

Hemostatics are therapeutic agents designed to control or prevent bleeding by promoting clot formation, stabilizing fibrin, enhancing platelet function, or correcting coagulation factor deficiencies. These drugs include systemic agents such as vitamin K, antifibrinolytics (e.g., tranexamic acid), desmopressin, and coagulation factor concentrates, as well as local hemostatics like thrombin preparations, collagen sponges, and fibrin sealants. Their mechanisms involve augmenting the coagulation cascade, inhibiting fibrinolysis, increasing platelet adhesion, or providing physical matrices that facilitate clot stabilization. Hemostatics are indispensable in managing surgical bleeding, trauma, hemorrhagic disorders, anticoagulant overdose, and genetic conditions such as hemophilia. While highly effective, inappropriate use may lead to thrombosis, disseminated intravascular coagulation, or organ ischemia, necessitating careful monitoring and individualized therapy. Hemostatics remain fundamental in emergency medicine, surgery, hematology, and critical care.